JNJ's REMICADE Holds: PFE's Results To Confirm

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

<p>This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to <a href="https://www.smartkarma.com/entities/991" target="_blank" data-smartkarma-citation="entities:991:1">Celltrion Inc (068270 KS)</a>, <a href="https://www.smartkarma.com/entities/992" target="_blank" data-smartkarma-citation="entities:992:1">Celltrion Pharm Inc (068760 KS)</a>, and <a href="https://www.smartkarma.com/entities/22932" target="_blank" data-smartkarma-citation="entities:22932:1">Samsung Biologics Co., Ltd (207940 KS)</a>, not to mention the planned listing of <a href="https://www.smartkarma.com/entities/23641" target="_blank" data-smartkarma-citation="entities:23641:1">Celltrion Healthcare (CELLHZ KS)</a>.  The topics of interest are 1) USFDA's draft guidance on interchangeability (important to all companies), 2) insurance coverage for Celltrion's Inflectra, and 3) US analysts' expectations for Inflectra's revenue. In summary, these developments are negative for the Celltrion complex relative to management's expectations for Inflectra. The implications for Samsung Biologics are mixed, but could have a positive impact long term.  </p><p>See the Insight streams for Celltrion Inc, and Samsung Biologics for background information.</p>

This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to Celltrion Inc (068270 KS), Celltrion Pharm Inc (068760 KS), and Samsung Biologics Co., Ltd (207940 KS), not to mention the planned listing of Celltrion Healthcare (CELLHZ KS).  The topics of interest are 1) USFDA's draft guidance on interchangeability (important to all companies), 2) insurance coverage for Celltrion's Inflectra, and 3) US analysts' expectations for Inflectra's revenue. In summary, these developments are negative for the Celltrion complex relative to management's expectations for Inflectra. The implications for Samsung Biologics are mixed, but could have a positive impact long term.  See the Insight streams for Celltrion Inc, and Samsung Biologics for background information.

Celltrion Inc

Recent Developments Not Encouraging